Kimberly White/Getty Images for Vanity Fair
23andMe raised an additional $250 million in 2017.
There was no shortage in healthcare and biotech startup funding in 2017.
By the end of 2017, a new crop of unicorns were born, while others increased their billion-dollar+ valuations.
From companies harnessing the plant microbiome to buzzy biotechs working on cutting-edge technology, here are the unicorns to keep an eye on in 2018, ranked by valuation.
Unless otherwise noted, valuations are according to PitchBook.